Section B Clinical experience with lorazepam in the treatment of neurotic patients

Publisher Website
Google Scholar
Abstract
A double-blind crossover study was designed to compare the anxiolytic properties of the benzodiazepines, lorazepam and diazepam, and to evaluate the principal side-effects prior to lorazepam's wider use in patients. Thirty patients with psychic or somatic symptoms of anxiety were given one active drug for a month, a placebo for 15 days and the other active drug for one month. Both lorazepam 1.25 mg. t.d.s., and diazepam 5 mg. t.d.s., alleviated anxiety to the same extent and gave a similar incidence of side-effects. Further use of lorazepam in a large number of patients has shown that most benefit from 1 mg. t.d.s. This dose could be increased progressively to 2.5 mg. t.d.s. It is suggested that lorazepam deserves particular attention since it is the most potent member of the benzodiazepine anxiolytics in clinical use.

This publication has 1 reference indexed in Scilit: